Global Breast Cancer Screening Tests Market, By Diagnostic Test Type (Blood Marker Tests, Imaging Test [Mammography, MRI screening test, Molecular Breast Imaging Test, PET scan, Ultrasound], Genetic Test [Fluorescence In Situ Hybridization, HER gene test], Immunohistochemistry Test) By End-User (Hospitals, Diagnostic Centers, Cancer Institutes, Research Laboratories), and opportunities and forecast 2020-2027
Breast Cancer Screening Tests Market Overview
Breast cancer is one of the most frequent cancers in women worldwide, and it is a leading cause of death. As a result, many disorders require early identification. Due to sophisticated lifestyles, breast cancer is more common in developed countries; nevertheless, the rate of occurrence is predicted to climb in emerging countries. The global Breast Cancer Screening Tests market is projected to boost at a significant rate in the forthcoming years. According to World Health Organization, in 2020, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally. As of the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past 5 years, making it the world’s most prevalent cancer.
Women's education and living standards have improved, resulting in later first pregnancies and a shorter lactation period, which has resulted in fluctuating hormone levels and a higher risk of breast cancer. Breast cancer risk rises as people get older. As a result, an increase in the elderly population is a major contributor to the growth in breast cancer incidence. The market is being driven by the rising incidence of breast cancer, growing awareness about breast cancer screening tests, government initiatives for breast cancer screening programs, technical advancements in breast imaging technologies, and the government's implementation of national-level programs for early diagnosis.
Report Metric
Details
Market size available for years
2019–2027
Base year considered
2019
Forecast period
2020–2027
Forecast unit
Value (USD Million)
Segments covered
Diagnostic Test Type, End-User, and Region
Regions covered
North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA)
Companies covered
A&G Pharmaceutical, Inc., Biocrates Life Sciences AG, Metabolomic Technologies, Inc., Myriad Genetics, Siemens Healthcare Diagnostics, Inc., OncoCyte Corporation, POC Medical Systems, Inc., Hologic, Inc., Provista Diagnostics, Inc., BioTime, Inc.
Covid-19 Impact on Breast Cancer Screening Tests Market
In addition, the current Breast Cancer Screening Tests Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Breast Cancer Screening Tests Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Breast Cancer Screening Tests Market Segment Overview
Based on diagnostic test type, the Imaging test is one of the most important segments in the global breast cancer screening tests market. The imaging test is the most commonly used test for the screening of breast cancer. This segment is divided into mammography, MRI screening test, molecular breast imaging test, PET scan, and ultrasound. Mammography is the most common test used for the detection of breast cancer. Mammography is the most popular breast cancer screening test in most developed nations since it is included in the breast screening program. By the end-user, the diagnostic center is a major segment of the market. The expansion of the diagnostic centers segment is aided by national breast cancer screening programs and increased awareness of breast cancer genetic transmission.
Breast Cancer Screening Tests Market, By Diagnostic Test Type
Blood Marker Tests
Imaging Test
Mammography
MRI screening test
Molecular Breast Imaging Test
PET scan
Ultrasound
Genetic Test
Fluorescence In Situ Hybridization
HER gene test
Immunohistochemistry Test
Breast Cancer Screening Tests Market, By End-User · Hospitals · Diagnostic Centers · Cancer Institutes · Research Laboratories
Breast Cancer Screening Tests Market Regional Overview
Region-Wise, North America held the largest share in the Breast Cancer Screening Tests market. This is because 70% of women in the U.S. undergo mammography. Furthermore, Europe is another major region for the market. Germany is expected to dominate the market in Europe This is due to advanced health care infrastructure and government-supported screening programs. Again, the market in the Asia Pacific is projected to rise at a considerable rate in the coming years. Availability of screening services in private health care and diagnostic centers is predicted to drive the market in developing countries such as India.
Breast Cancer Screening Tests Market, By Geography
· North America (US & Canada) · Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe) · Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific) · LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Breast Cancer Screening Tests Market, Key Players
· A&G Pharmaceutical, Inc. · Biocrates Life Sciences AG · Metabolomic Technologies, Inc. · Myriad Genetics · Siemens Healthcare Diagnostics, Inc. · OncoCyte Corporation · POC Medical Systems, Inc. · Hologic, Inc. · Provista Diagnostics, Inc. · BioTime, Inc.
Frequently Asked Questions (FAQ) :
Q1. What are the driving factors for the Breast Cancer Screening Tests market?
A. The market is being driven by the rising incidence of breast cancer, growing awareness about breast cancer screening tests, government initiatives for breast cancer screening programs, technical advancements in breast imaging technologies, and the government's implementation of national-level programs for early diagnosis.
Q2. Which Segments are covered in the Breast Cancer Screening Tests Market report?
A. Diagnostic Test Type, End-User, and Region. these segments are covered in the Breast Cancer Screening Tests Market report.
Q3. Which segment is projected to hold the largest share in the Breast Cancer Screening Tests Market?
A. The imaging test segment is projected to hold the largest share in the Breast Cancer Screening Tests Market.
Q4. Which region holds the largest share in the Breast Cancer Screening Tests market?
A. North America held the largest share in the global Breast Cancer Screening Tests Market
Q5. Which are the prominent players in the Breast Cancer Screening Tests Market?
A. A&G Pharmaceutical, Inc., Biocrates Life Sciences AG, Metabolomic Technologies, Inc., Myriad Genetics, Siemens Healthcare Diagnostics, Inc., OncoCyte Corporation, POC Medical Systems, Inc., Hologic, Inc., Provista Diagnostics, Inc., BioTime, Inc. are some key players in the Breast Cancer Screening Tests Market.
Breast Cancer Screening Tests Market Study Global Market Analysis, Insights and Forecast, 2020-2027
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Key Emerging Trends – For Major Countries
4.2. Latest Technological Advancement
4.3. Regulatory Landscape
4.4. Industry SWOT Analysis
4.5. Porters Five Forces Analysis
5. Global Breast Cancer Screening Tests Market Analysis (USD Billion), Insights and Forecast, 2020-2027
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Diagnostic Test Type
5.2.1. Blood Marker Tests
5.2.2. Imaging Test
5.2.2.1. Mammography
5.2.2.2. MRI screening test
5.2.2.3. Molecular Breast Imaging Test
5.2.2.4. PET scan
5.2.2.5. Ultrasound
5.2.3. Genetic Test
5.2.3.1. Fluorescence In Situ Hybridization
5.2.3.2. HER gene test
5.2.4. Immunohistochemistry Test
5.3. Market Analysis, Insights and Forecast – By End-User
5.3.1. Hospitals
5.3.2. Diagnostic Centers
5.3.3. Cancer Institutes
5.3.4. Research Laboratories
5.4. Market Analysis, Insights and Forecast – By Region
5.4.1. North America
5.4.2. Europe
5.4.3. Asia Pacific
5.4.4. Latin America, Middle East and Africa
6. North America Breast Cancer Screening Tests Market Analysis (USD Billion), Insights and Forecast, 2020-2027
6.1. Key Findings / Summary
6.2. Market Analysis, Insights and Forecast – By Diagnostic Test Type
6.2.1. Blood Marker Tests
6.2.2. Imaging Test
6.2.2.1. Mammography
6.2.2.2. MRI screening test
6.2.2.3. Molecular Breast Imaging Test
6.2.2.4. PET scan
6.2.2.5. Ultrasound
6.2.3. Genetic Test
6.2.3.1. Fluorescence In Situ Hybridization
6.2.3.2. HER gene test
6.2.4. Immunohistochemistry Test
6.3. Market Analysis, Insights and Forecast – By End-User
6.3.1. Hospitals
6.3.2. Diagnostic Centers
6.3.3. Cancer Institutes
6.3.4. Research Laboratories
6.4. Market Analysis, Insights and Forecast – By Country
6.4.1. U.S.
6.4.2. Canada
7. Europe Breast Cancer Screening Tests Market Analysis (USD Billion), Insights and Forecast, 2020-2027
7.1. Key Findings / Summary
7.2. Market Analysis, Insights and Forecast – By Diagnostic Test Type
7.2.1. Blood Marker Tests
7.2.2. Imaging Test
7.2.2.1. Mammography
7.2.2.2. MRI screening test
7.2.2.3. Molecular Breast Imaging Test
7.2.2.4. PET scan
7.2.2.5. Ultrasound
7.2.3. Genetic Test
7.2.3.1. Fluorescence In Situ Hybridization
7.2.3.2. HER gene test
7.2.4. Immunohistochemistry Test
7.3. Market Analysis, Insights and Forecast – By End-User
7.3.1. Hospitals
7.3.2. Diagnostic Centers
7.3.3. Cancer Institutes
7.3.4. Research Laboratories
7.4. Market Analysis, Insights and Forecast – By Country
7.4.1. UK
7.4.2. Germany
7.4.3. France
7.4.4. Italy
7.4.5. Spain
7.4.6. Russia
7.4.7. Rest of Europe
8. Asia Pacific Breast Cancer Screening Tests Market Analysis (USD Billion), Insights and Forecast, 2020-2027
8.1. Key Findings / Summary
8.2. Market Analysis, Insights and Forecast – By Diagnostic Test Type
8.2.1. Blood Marker Tests
8.2.2. Imaging Test
8.2.2.1. Mammography
8.2.2.2. MRI screening test
8.2.2.3. Molecular Breast Imaging Test
8.2.2.4. PET scan
8.2.2.5. Ultrasound
8.2.3. Genetic Test
8.2.3.1. Fluorescence In Situ Hybridization
8.2.3.2. HER gene test
8.2.4. Immunohistochemistry Test
8.3. Market Analysis, Insights and Forecast – By End-User
8.3.1. Hospitals
8.3.2. Diagnostic Centers
8.3.3. Cancer Institutes
8.3.4. Research Laboratories
8.4. Market Analysis, Insights and Forecast – By Country
8.4.1. China
8.4.2. India
8.4.3. Japan
8.4.4. Australia
8.4.5. South East Asia
8.4.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Breast Cancer Screening Tests Market Analysis (USD Billion), Insights and Forecast, 2020-2027
9.1. Key Findings / Summary
9.2. Market Analysis, Insights and Forecast – By Diagnostic Test Type
9.2.1. Blood Marker Tests
9.2.2. Imaging Test
9.2.2.1. Mammography
9.2.2.2. MRI screening test
9.2.2.3. Molecular Breast Imaging Test
9.2.2.4. PET scan
9.2.2.5. Ultrasound
9.2.3. Genetic Test
9.2.3.1. Fluorescence In Situ Hybridization
9.2.3.2. HER gene test
9.2.4. Immunohistochemistry Test
9.3. Market Analysis, Insights and Forecast – By End-User
9.3.1. Hospitals
9.3.2. Diagnostic Centers
9.3.3. Cancer Institutes
9.3.4. Research Laboratories
9.4. Market Analysis, Insights and Forecast – By Country
9.4.1. Brazil
9.4.2. Saudi Arabia
9.4.3. UAE
9.4.4. Rest of LAMEA
10. Competitive Analysis
10.1. Company Market Share Analysis, 2018
10.2. Key Industry Developments
10.3. Company Profile
10.4. A&G Pharmaceutical, Inc.
10.4.1. Business Overview
10.4.2. Segment 1 & Service Offering
10.4.3. Overall Revenue
10.4.4. Geographic Presence
10.4.5. Recent Development
*Similar details will be provided for the following companies
10.5. Biocrates Life Sciences AG
10.6. Metabolomic Technologies, Inc.
10.7. Myriad Genetics
10.8. Siemens Healthcare Diagnostics, Inc.
10.9. OncoCyte Corporation
10.10. POC Medical Systems, Inc.
10.11. Hologic, Inc.
10.12. Provista Diagnostics, Inc.
List of Figures
Figure 1: Global Breast Cancer Screening Market Revenue Breakdown (USD Billion, %) by Region, 2019 & 2027
Figure 2: Global Breast Cancer Screening Market Value Share (%), By Segment 1, 2019 & 2027
Figure 3: Global Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 4: Global Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 5: Global Breast Cancer Screening Market Value Share (%), By Segment 2, 2019 & 2027
Figure 6: Global Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 7: Global Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 8: Global Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 9: Global Breast Cancer Screening Market Forecast (USD Billion), by Others, 2016-2027
Figure 10: Global Breast Cancer Screening Market Value Share (%), By Segment 3, 2019 & 2027
Figure 11: Global Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 12: Global Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 13: Global Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 14: Global Breast Cancer Screening Market Forecast (USD Billion), by Others, 2016-2027
Figure 15: Global Breast Cancer Screening Market Value (USD Billion), by Region, 2019 & 2027
Figure 16: North America Breast Cancer Screening Market Value Share (%), By Segment 1, 2019 & 2027
Figure 17: North America Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 18: North America Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 19: North America Breast Cancer Screening Market Value Share (%), By Segment 2, 2019 & 2027
Figure 20: North America Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 21: North America Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 22: North America Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 23: North America Breast Cancer Screening Market Forecast (USD Billion), by Others, 2016-2027
Figure 24: North America Breast Cancer Screening Market Value Share (%), By Segment 3, 2019 & 2027
Figure 25: North America Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 26: North America Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 27: North America Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 28: North America Breast Cancer Screening Market Forecast (USD Billion), by Others, 2016-2027
Figure 29: North America Breast Cancer Screening Market Forecast (USD Billion), by U.S., 2016-2027
Figure 30: North America Breast Cancer Screening Market Forecast (USD Billion), by Canada, 2016-2027
Figure 31: Latin America Breast Cancer Screening Market Value Share (%), By Segment 1, 2019 & 2027
Figure 32: Latin America Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 33: Latin America Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 34: Latin America Breast Cancer Screening Market Value Share (%), By Segment 2, 2019 & 2027
Figure 35: Latin America Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 36: Latin America Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 37: Latin America Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 38: Latin America Breast Cancer Screening Market Forecast (USD Billion), by Others, 2016-2027
Figure 39: Latin America Breast Cancer Screening Market Value Share (%), By Segment 3, 2019 & 2027
Figure 40: Latin America Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 41: Latin America Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 42: Latin America Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 43: Latin America Breast Cancer Screening Market Forecast (USD Billion), by Others, 2016-2027
Figure 44: Latin America Breast Cancer Screening Market Forecast (USD Billion), by Brazil, 2016-2027
Figure 45: Latin America Breast Cancer Screening Market Forecast (USD Billion), by Mexico, 2016-2027
Figure 46: Latin America Breast Cancer Screening Market Forecast (USD Billion), by Rest of Latin America, 2016-2027
Figure 47: Europe Breast Cancer Screening Market Value Share (%), By Segment 1, 2019 & 2027
Figure 48: Europe Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 49: Europe Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 50: Europe Breast Cancer Screening Market Value Share (%), By Segment 2, 2019 & 2027
Figure 51: Europe Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 52: Europe Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 53: Europe Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 54: Europe Breast Cancer Screening Market Forecast (USD Billion), by Others, 2016-2027
Figure 55: Europe Breast Cancer Screening Market Value Share (%), By Segment 3, 2019 & 2027
Figure 56: Europe Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 57: Europe Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 58: Europe Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 59: Europe Breast Cancer Screening Market Forecast (USD Billion), by Others, 2016-2027
Figure 60: Europe Breast Cancer Screening Market Forecast (USD Billion), by U.K., 2016-2027
Figure 61: Europe Breast Cancer Screening Market Forecast (USD Billion), by Germany, 2016-2027
Figure 62: Europe Breast Cancer Screening Market Forecast (USD Billion), by France, 2016-2027
Figure 63: Europe Breast Cancer Screening Market Forecast (USD Billion), by Italy, 2016-2027
Figure 64: Europe Breast Cancer Screening Market Forecast (USD Billion), by Spain, 2016-2027
Figure 65: Europe Breast Cancer Screening Market Forecast (USD Billion), by Russia, 2016-2027
Figure 66: Europe Breast Cancer Screening Market Forecast (USD Billion), by Rest of Europe, 2016-2027
Figure 67: Asia Pacific Breast Cancer Screening Market Value Share (%), By Segment 1, 2019 & 2027
Figure 68: Asia Pacific Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 69: Asia Pacific Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 70: Asia Pacific Breast Cancer Screening Market Value Share (%), By Segment 2, 2019 & 2027
Figure 71: Asia Pacific Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 72: Asia Pacific Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 73: Asia Pacific Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 74: Asia Pacific Breast Cancer Screening Market Forecast (USD Billion), by Others, 2016-2027
Figure 75: Asia Pacific Breast Cancer Screening Market Value Share (%), By Segment 3, 2019 & 2027
Figure 76: Asia Pacific Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 77: Asia Pacific Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 78: Asia Pacific Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 79: Asia Pacific Breast Cancer Screening Market Forecast (USD Billion), by Others, 2016-2027
Figure 80: Asia Pacific Breast Cancer Screening Market Forecast (USD Billion), by China, 2016-2027
Figure 81: Asia Pacific Breast Cancer Screening Market Forecast (USD Billion), by India, 2016-2027
Figure 82: Asia Pacific Breast Cancer Screening Market Forecast (USD Billion), by Japan, 2016-2027
Figure 83: Asia Pacific Breast Cancer Screening Market Forecast (USD Billion), by Australia, 2016-2027
Figure 84: Asia Pacific Breast Cancer Screening Market Forecast (USD Billion), by Southeast Asia, 2016-2027
Figure 85: Asia Pacific Breast Cancer Screening Market Forecast (USD Billion), by Rest of Asia Pacific, 2016-2027
Figure 86: Middle East & Africa Breast Cancer Screening Market Value Share (%), By Segment 1, 2019 & 2027
Figure 87: Middle East & Africa Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 88: Middle East & Africa Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 89: Middle East & Africa Breast Cancer Screening Market Value Share (%), By Segment 2, 2019 & 2027
Figure 90: Middle East & Africa Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 91: Middle East & Africa Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 92: Middle East & Africa Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 93: Middle East & Africa Breast Cancer Screening Market Forecast (USD Billion), by Others, 2016-2027
Figure 94: Middle East & Africa Breast Cancer Screening Market Value Share (%), By Segment 3, 2019 & 2027
Figure 95: Middle East & Africa Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 96: Middle East & Africa Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 97: Middle East & Africa Breast Cancer Screening Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 98: Middle East & Africa Breast Cancer Screening Market Forecast (USD Billion), by Others, 2016-2027
Figure 99: Middle East & Africa Breast Cancer Screening Market Forecast (USD Billion), by GCC, 2016-2027
Figure 100: Middle East & Africa Breast Cancer Screening Market Forecast (USD Billion), by South Africa, 2016-2027
Figure 101: Middle East & Africa Breast Cancer Screening Market Forecast (USD Billion), by Rest of Middle East & Africa, 2016-2027
List of Tables
Table 1: Global Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
Table 2: Global Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
Table 3: Global Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
Table 4: Global Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Region, 2016-2027
Table 5: North America Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
Table 6: North America Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
Table 7: North America Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
Table 8: North America Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Country, 2016-2027
Table 9: Europe Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
Table 10: Europe Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
Table 11: Europe Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
Table 12: Europe Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Country, 2016-2027
Table 13: Latin America Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
Table 14: Latin America Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
Table 15: Latin America Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
Table 16: Latin America Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Country, 2016-2027
Table 17: Asia Pacific Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
Table 18: Asia Pacific Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
Table 19: Asia Pacific Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
Table 20: Asia Pacific Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Country, 2016-2027
Table 21: Middle East & Africa Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
Table 22: Middle East & Africa Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
Table 23: Middle East & Africa Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
Table 24: Middle East & Africa Breast Cancer Screening Market Revenue (USD Billion) Forecast, by Country, 2016-2027
